(28 days)
No
The description focuses on the mechanical function of the orthosis and the practitioner's manual modification based on 3D imaging, with no mention of AI or ML algorithms for analysis, modification, or treatment planning.
Yes
The device is intended for medical purposes to improve cranial symmetry and/or shape in infants with positional plagiocephaly by applying mild pressure to prominent regions of the cranium, indicating a therapeutic intent to correct a medical condition.
No
The device is a cranial orthosis designed to treat positional plagiocephaly by redirecting head growth, not to diagnose a condition. While it uses 3D imaging to capture the head's shape for treatment planning, this imaging is part of the treatment process itself, not for diagnostic determination.
No
The device description clearly states that the STARband® 3D™ is a physical band that is applied to the infant's head, indicating it is a hardware device, not software-only. While it utilizes 3D imaging and potentially software for design modification, the core medical device is the physical orthosis.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- STARband® 3D™ Function: The STARband® 3D™ is a cranial orthosis, a physical device worn on the head. Its purpose is to apply pressure to reshape the infant's skull. It does not analyze any biological samples from the patient.
- Intended Use: The intended use clearly states it's for applying pressure to the cranium to improve symmetry and shape, not for analyzing biological specimens for diagnostic purposes.
The device uses 3D imaging to create a custom-fit orthosis, but this imaging is used for the design and manufacturing of the physical device, not for analyzing biological markers or substances.
N/A
Intended Use / Indications for Use
The STARband® 3D™ is intended for medical purposes for use on infants from 3 to 18 months of age, with moderate to severe non-synostotic positional plagiocephaly, including infants with plagiocephalic, brachycephalic and scaphocephalic-shaped heads by applying mild pressure to prominent regions of the infant's cranium to improve cranial symmetry and/or shape.
Product codes
OAN, MVA
Device Description
The STARband® 3D™ redirects the head growth to improve proportion and symmetry. The practitioner takes a 3-dimensional captured image of the infant's head to acquire the existing shape. The 3-dimensional positive model is modified to obtain greater symmetry and space in the areas of flattening. The STARband® 3D™ provides total contact over the prominent or bossed areas of the baby's head to discourage growth there. Over the course of treatment, the inside of the band is further modified by the practitioner to provide space for growth to occur in the flat or depressed areas. The shape of the STARband® 3D™ directs growth into the areas of least resistance and creates a precise pathway for the head shape to improve in symmetry and proportion.
Mentions image processing
The practitioner takes a 3-dimensional captured image of the infant's head to acquire the existing shape. The 3-dimensional positive model is modified to obtain greater symmetry and space in the areas of flattening.
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Previously cleared 3-dimensional imaging devices: STARscanner I, STARscanner II, Spectra 3D Scanner, M4DScan/BodyScan System, 3dMDhead System, 3dMDcranial System, 3dMDflex System, SmartSoc System for Android and iOS devices
Anatomical Site
Cranium/Head
Indicated Patient Age Range
infants from 3 to 18 months of age
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-Clinical Performance tests conducted for the predicate and reference devices, and referenced in this submission, passed all verification and validation acceptance criteria and demonstrated their safety and effectiveness. Given that the change proposed for the subject device requires no additional performance testing, these tests remain valid for the subject device, and they support the determination of substantial equivalence between the proposed device and the predicate device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 882.5970 Cranial orthosis.
(a)
Identification. A cranial orthosis is a device that is intended for medical purposes to apply pressure to prominent regions of an infant's cranium in order to improve cranial symmetry and/or shape in infants from 3 to 18 months of age, with moderate to severe nonsynostotic positional plagiocephaly, including infants with plagiocephalic-, brachycephalic-, and scaphocephalic-shaped heads.(b)
Classification. Class II (special controls) (prescription use in accordance with § 801.109 of this chapter, biocompatibility testing, and labeling (contraindications, warnings, precautions, adverse events, instructions for physicians and parents)).
0
March 15, 2024
Image /page/0/Picture/1 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
Orthomerica Products Inc. Najiba Katir Regulatory Compliance Manager 6333 North Orange Blossom Trail Orlando, Florida 32810
Re: K240466
Trade/Device Name: STARband 3D Regulation Number: 21 CFR 882.5970 Regulation Name: Cranial Orthosis Regulatory Class: Class II Product Code: OAN, MVA Dated: February 16, 2024 Received: February 16, 2024
Dear Najiba Katir:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
1
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely, Digitally signed Adam D . by Adam D. Pierce -S Pierce -S Date: 2024.03.15 09:19:21 -04'00'
Adam D. Pierce, Ph.D. Assistant Director DHT5A: Division of Neurosurgical, Neurointerventional and Neurodiagnostic Devices OHT5: Office of Neurological
2
and Physical Medicine Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
Submission Number (if known)
Device Name
STARband 3D
Indications for Use (Describe)
The STARband® 3D™ is intended for medical purposes for use on infants from 3 to 18 months of age, with moderate to severe non-synostotic positional plagiocephaly, including infants with plagiocephalic, brachycephalic and scaphocephalic-shaped heads by applying mild pressure to prominent regions of the infant's cranium to improve cranial symmetry and/or shape.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
510(k) Summary
I. Applicant Information
| Name: | Orthomerica Products, Inc. |
|---|---|
| Address: | 6333 North Orange Blossom Trail |
| Orlando, FL 32810 | |
| Telephone: | (407) 290-6592 |
| Facsimile: | (407) 290-2419 |
FDA Establishment Registration Number
1058152
Contact Information
| Contact Person: | Najiba Katir, Regulatory Compliance Manager |
|---|---|
| Address: | 6333 North Orange Blossom Trail |
| Orlando, FL 32810 | |
| Telephone: | (407) 290-6592 |
| Facsimile: | (407) 290-2419 |
| Email: | nkatir@orthomerica.com |
| Date Prepared: | March 13th, 2024 |
II. Device Information
STARband® 3D™ Proprietary Name: Classification: Class II (special controls); OAN; MVA; 21 CFR 882.5970 Classification Name: Cranial Orthosis
Legally Marketed Predicate Device and Reference Device VI.
- Predicate Device: STARband® 3D™ Cranial Orthosis K223238 I
- I Reference Device: STARband® Cranial Orthosis - K211376
IV. Device Description/Modification Summary
The STARband® 3D™ redirects the head growth to improve proportion and symmetry. The practitioner takes a 3-dimensional captured image of the infant's head to acquire the existing shape. The 3-dimensional positive model is modified to obtain greater symmetry and space in the areas of flattening. The STARband® 3D™ provides total contact over the prominent or bossed areas of the baby's head to discourage growth there. Over the course of treatment, the inside of the band is further modified by the practitioner to provide
5
space for growth to occur in the flat or depressed areas. The shape of the STARband® 3D™ directs growth into the areas of least resistance and creates a precise pathway for the head shape to improve in symmetry and proportion.
Proposed Modification:
The STARband® 3D™ cranial orthosis device proposed in this submission has identical indications for use to the predicate submission K223238. The difference with this proposed device is the addition of scanning technologies which were already cleared by Orthomerica Products Inc. for use with its reference device K211376 and have undergone no change since the reference device clearance.
The indications for use, the intended use, and the underlying principles of operation of the STARband® 3D™ cranial orthosis remain the same.
V. Indications for Use and Intended Use
Indications for Use:
The STARband® 3D™ is intended for medical purposes for use on infants from three to 18 months of age, with moderate to severe non-synostotic positional plagiocephaly, including infants with plagiocephalic-, brachycephalic-, and scaphocephalic- shaped heads by applying mild pressure to prominent regions of the infant's cranium in order to improve cranial symmetry and/or shape.
Intended Use:
The STARband® 3D™ is designed to treat infants with abnormal head shapes from age 3 to 18 months and is available by prescription only. Since growth is the driving factor in head shape correction, the infants wear the STARband® 3D™ for approximately 23 hours per day. The most common head deformities are positional plagiocephaly, brachycephaly, and scaphocephaly. The same principles of cranial remolding apply to positional deformities.
Indications for Use Comparison
The indications for use of the proposed device are identical to the ones of the predicate device and the reference device.
6
Summary of Technological Characteristics Comparison VII.
The STARband® 3D™ cranial orthosis device proposed in this submission has the same indications for use, intended use, underlying principles of operations and basic design as the predicate device as illustrated in Table 1 below.
| Device
| Characteristic | Subject Device | Predicate Device K223238 | Reference Device K211376 |
|---|---|---|---|
| Manufacturer | Orthomerica Products, Inc. | Orthomerica Products, Inc. | Orthomerica Products, Inc. |
| Trade Name | STARband 3D | STARband 3D | STARband |
| Product Code | OAN, MVA | OAN, MVA | OAN, MVA |
| Intended Use | Maintains total contact over | ||
| areas of bossing or | |||
| protrusion and creates voids | |||
| over areas of depression or | |||
| flattening to redirect cranial | |||
| growth toward greater | |||
| symmetry. | Maintains total contact over | ||
| areas of bossing or | |||
| protrusion and creates voids | |||
| over areas of depression or | |||
| flattening to redirect cranial | |||
| growth toward greater | |||
| symmetry. | Maintains total contact over | ||
| areas of bossing or | |||
| protrusion and creates voids | |||
| over areas of depression or | |||
| flattening to redirect cranial | |||
| growth toward greater | |||
| symmetry. | |||
| Contraindications | Not for use on infants with | ||
| synostosis or hydrocephalus | Not for use on infants with | ||
| synostosis or hydrocephalus | Not for use on infants with | ||
| synostosis or hydrocephalus | |||
| Prescription | |||
| required? | Prescription Use Only | Prescription Use Only | Prescription Use Only |
| Size Options | Patient-matched sizing by | ||
| scanning an image of | |||
| patient's head shape | Patient-matched sizing by | ||
| scanning an image of | |||
| patient's head shape | Patient-matched sizing by | ||
| scanning an image of | |||
| patient's head shape or | |||
| plaster mold to make | |||
| positive mold of head shape | |||
| Software Used for | |||
| Shape | CAD software is used to | ||
| modify the shape of the | |||
| scanned image to improve | |||
| symmetry and shape of the | |||
| helmet to be manufactured | CAD software is used to | ||
| modify the shape of the | |||
| scanned image to improve | |||
| symmetry and shape of the | |||
| helmet to be manufactured | Customized and/or CAD | ||
| software may be used to | |||
| modify the shape of the | |||
| scanned image to improve | |||
| symmetry and shape of the | |||
| helmet to be manufactured | |||
| Design | |||
| Components | Polymer helmet with bi- | ||
| lateral side-opening, | |||
| closures, and zone padded | |||
| lining | Polymer helmet with bi- | ||
| lateral side-opening, | |||
| closures, and zone padded | |||
| lining | Polymer helmet with side | ||
| opening closure and padded | |||
| lining | |||
| Approximate | |||
| Device | |||
| Weight | 4 – 6.5 oz | 4 – 6.5 oz | 6 – 10 oz |
| Device | |||
| Characteristic | Subject Device | Predicate Device K223238 | Reference Device K211376 |
| Manufacturing | |||
| Process | Additively manufactured | ||
| orthosis based upon | |||
| measurements of the | |||
| infant's head captured by | |||
| previously cleared 3- | |||
| dimensional imaging devices | Additively manufactured | ||
| orthosis based upon | |||
| measurements of the | |||
| infant's head captured by a | |||
| previously cleared 3- | |||
| dimensional imaging device | - Form orthosis from a | ||
| positive mold of infant's | |||
| head |
- Positive mold is formed
based upon measurements
of the infant's head taken by
an approved 3-dimensional
imaging device from which a
3-dimensional image is made
or from a traditional plaster
cast - The 3-dimensional image is
used to produce a positive
mold using a 5-axis routing
machine |
| Approved 3-
Dimensional
Imaging Devices | STARscanner I
STARscanner II
Spectra 3D Scanner
M4DScan/BodyScan System
3dMDhead System
3dMDcranial System
3dMDflex System
SmartSoc System for
Android and iOS devices | STARscanner I
STARscanner II | Spectra 3D Scanner
M4DScan/BodyScan System
Omega Scanner
3dMDhead System
3dMDcranial System
3dMDflex System
scanGogh-II
STARscanner I
STARscanner II
SmartSoc System for Android
and iOS devices |
| Testing | Nonclinical performance
testing performed for the
predicate device and
reference device remains
applicable as there was no
design change to the device.
Validation was conducted to
evaluate one potential risk
identified during design
control activities and no
impact on safety or
effectiveness was identified.
These tests are referenced
in the submission | Test samples were additively
manufactured from 3D
images of representative
cranial shapes using previous
cleared scanning device(s).
Process Validation included
Dimensional Analysis, Fit
Assessment and Mechanical
Testing of test samples to
evaluate the additive
manufacturing process
performance, which was
compared to the process
used for the predicate
device. | Cranial Shape Capture
Accuracy Study utilized a
representative cranial shape
that possesses a predefined
shape with known
dimensions, which compared
proposed device to cast and
predicate device. Associated
parameters analyzed
included coordinate planes
(A-P; M-L; P-D) and various
radius parameters,
squareness, and flatness. |
| Biocompatibility | Material Biocompatibility
Testing
Same as predicate | Material Biocompatibility
Testing
●
Cytotoxicity
●
Sensitization
●
Irritation | Material Biocompatibility
Testing
●
Cytotoxicity
●
Sensitization
●
Irritation |
Table 1 – Comparison of Subject Device, Predicate Device, and Reference Device.
7
8
VIII. Summary and Conclusion of Non-Clinical Performance Data
Non-Clinical Performance tests conducted for the predicate and reference devices, and referenced in this submission, passed all verification and validation acceptance criteria and demonstrated their safety and effectiveness. Given that the change proposed for the subject device requires no additional performance testing, these tests remain valid for the subject device, and they support the determination of substantial equivalence between the proposed device and the predicate device.
IX. Conclusion on Substantial Equivalence
The STARband® 3D™ cranial orthosis device proposed in this submission is substantially equivalent to the predicate device in K223238, given that it has the same indications for use, intended use, and underlying principles of operation and that previous non-clinical performance test results support that determination.